Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,757.46
(
-1.55%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.15
(
7.45%
)
Bitcoin
71,090.59
(
-3.86%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2637
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: genisi post# 151630

Friday, 11/02/2012 9:20:27 AM

Friday, November 02, 2012 9:20:27 AM

Post# of 257253

I think BIIB would be wise to price BG-12 below Gilenya and above Copaxone.



Agree.

If the premium to Copaxone is small, patients will move to BG12 and insurers will pick up coverage quickly and not use copays to discourage use.

It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now